Stock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates

Stock Track

Nov 05, 2025

MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and positive developments across its business operations.

The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34%. The revenue figure marks a substantial 17.20% increase from $70.079 million in the corresponding quarter of the previous year.

Beyond the financial results, MannKind shared several positive business updates. The FDA accepted the company's supplemental Biologics License Application for Afrezza's pediatric use, with a PDUFA date set for May 29, 2026. Additionally, MannKind completed the acquisition of scPharmaceuticals in October 2025, utilizing approximately $133.2 million of available cash and borrowing an additional $250.0 million in delayed draw term loans. These developments, coupled with progress in clinical trials for MNKD-101 and MNKD-201, underscore the company's commitment to growth and innovation in the biopharmaceutical sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1188878776"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188878776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188878776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188878776","market":"nz","top_or_hot":-1,"title":"Stock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates","media":"Stock Track","content":"<p>MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and positive developments across its business operations.</p>\n\n<p>The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34%. The revenue figure marks a substantial 17.20% increase from $70.079 million in the corresponding quarter of the previous year.</p>\n\n<p>Beyond the financial results, MannKind shared several positive business updates. The FDA accepted the company's supplemental Biologics License Application for Afrezza's pediatric use, with a PDUFA date set for May 29, 2026. Additionally, MannKind completed the acquisition of scPharmaceuticals in October 2025, utilizing approximately $133.2 million of available cash and borrowing an additional $250.0 million in delayed draw term loans. These developments, coupled with progress in clinical trials for MNKD-101 and MNKD-201, underscore the company's commitment to growth and innovation in the biopharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and positive developments across its business operations.</p>\n\n<p>The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34%. The revenue figure marks a substantial 17.20% increase from $70.079 million in the corresponding quarter of the previous year.</p>\n\n<p>Beyond the financial results, MannKind shared several positive business updates. The FDA accepted the company's supplemental Biologics License Application for Afrezza's pediatric use, with a PDUFA date set for May 29, 2026. Additionally, MannKind completed the acquisition of scPharmaceuticals in October 2025, utilizing approximately $133.2 million of available cash and borrowing an additional $250.0 million in delayed draw term loans. These developments, coupled with progress in clinical trials for MNKD-101 and MNKD-201, underscore the company's commitment to growth and innovation in the biopharmaceutical sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"","article_id":"1188878776","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188878776","pubTimestamp":1762348127,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"个股追踪|MannKind盘前飙升5.84%，第三季度业绩强劲，每股收益和营收超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"MannKind Corporation (NASDAQ:MNKD) saw its stock surge 5.84% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and positive developments across its business operations.\nThe company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34%. The revenue figure marks a substantial 17.20% increase from $70.079 million in the corresponding quarter of the previous year.\nBeyond the financial results, MannKind shared several positive business updates. The FDA accepted the company's supplemental Biologics License Application for Afrezza's pediatric use, with a PDUFA date set for May 29, 2026. Additionally, MannKind completed the acquisition of scPharmaceuticals in October 2025, utilizing approximately $133.2 million of available cash and borrowing an additional $250.0 million in delayed draw term loans. These developments, coupled with progress in clinical trials for MNKD-101 and MNKD-201, underscore the company's commitment to growth and innovation in the biopharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}